English version of this page

Vaskulær patofysiologi

Gruppens mål er å redusere forekomsten av hjerte- og karsykdom ved å utvikle nye diagnostiske metoder og behandlingsstrategier.

Røntgen av kranie fra en person som har fått slag. Berørt område farget med rødt.

Illustrasjon: Colourbox

Vi utfører grunnforskning i vaskulærbiologi med målsetting å forstå og finne løsninger på uløste problemer i hjerte- og karmedisin. Vi undersøker spesielt sirkulasjonsfaktorer som er komponenter i koagulasjons- og fibrinolysesystemet.

Forskningen er relevant for sykdommer som eksempelvis aterosklerose, hjerteinfarkt, slag og blodpropp. Mekanismene vi studerer er også relevante for lignende prosesser som vevsreparasjon, fibrose, forsvar mot infeksjon, inflammasjon og kreft.

Les mer på de engelske sidene til forskningsgruppen for vaskulær patofysiologi.

Samarbeid

  • Jonas Emsley, Nottingham, UK (Protein structure function, X-ray crystallography)
  • Christina Jern, Gothenburg, Sweden (Stroke diagnosis and GWAS)
  • Paul Declerck, Leuven, Belgium (Serine protease inhibitors and monoclonal antibodies)
  • Eric Camerer, Paris, France (Protease-activated receptors)
  • Denis Vivien, Caen, France (Mouse models of stroke)
  • Michael Etscheid, Langen, Germany (FSAP biochemistry and thrombosis)
  • Christoph Reichel, Munich, Germany (Proteases and leukocyte transmigration)
  • Trygve Braun Leergaard, Oslo, Norway (Rodent neuroanatomical mapping)
  • Per Morten Sandset, Oslo, Norway (Thrombosis)
  • Geir Åge Løset, Oslo, Norway (Phage display)
  • Hartmut Luecke, Oslo, Norway (Protein structure function, cryo-electron microscopy)
  • Kristi Bache, Oslo, Norway (Stroke-Diagnosis)

Publikasjoner


1.    Byskov K, Le Gall SM, Thiede B, Camerer E and Kanse SM. Protease activated receptors (PAR)-1 and -2 mediate cellular effects of factor VII activating protease (FSAP). The FASEB Journal. 2020; In press.
2.    Uslu O, Herold J and Kanse SM. VEGF-A-Cleavage by FSAP and Inhibition of Neo-Vascularization. Cells. 2019; 8.
3.    Rut W, Nielsen NV, Czarna J, Poreba M, Kanse SM and Drag M. Fluorescent activity-based probe for the selective detection of Factor VII activating protease (FSAP) in human plasma. Thrombosis research. 2019;182:124-132.
4.    Nielsen NV, Roedel E, Manna D, Etscheid M, Morth JP and Kanse SM. Characterization of the enzymatic activity of the serine protease domain of Factor VII activating protease (FSAP). Scientific Reports. 2019; In Press.
5.    Dahm AEA, Jacobsen EM, Wik HS, Jacobsen AF, Mollnes TE, Kanse SM and Sandset PM. Elevated Complement C3 and C4 Levels are Associated with Postnatal Pregnancy-Related Venous Thrombosis. Thromb Haemost. 2019;119:1481-1488.
6.    Bohnert BN, Kanse S, Haerteis S, Korbmacher C and Artunc F. Rebuttal to Editorial: sodium retention by uPA in nephrotic syndrome? Acta physiologica (Oxford, England). 2019:e13427.
7.    Bohnert BN, Daiminger S, Worn M, Sure F, Staudner T, Ilyaskin AV, Batbouta F, Janessa A, Schneider JC, Essigke D, Kanse S, Haerteis S, Korbmacher C and Artunc F. Urokinase-type plasminogen activator (uPA) is not essential for epithelial sodium channel (ENaC)-mediated sodium retention in experimental nephrotic syndrome. Acta physiologica (Oxford, England). 2019:e13286.
8.    Subramaniam S, Kanse SM, Kothari H, Reinhardt C and Fletcher C. Post-transcriptional, post-translational and pharmacological regulation of tissue factor pathway inhibitor. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2018;29:668-682.
9.    Praetner M, Zuchtriegel G, Holzer M, Uhl B, Schaubacher J, Mittmann L, Fabritius M, Furst R, Zahler S, Funken D, Lerchenberger M, Khandoga A, Kanse S, Lauber K, Krombach F and Reichel CA. Plasminogen Activator Inhibitor-1 Promotes Neutrophil Infiltration and Tissue Injury on Ischemia-Reperfusion. Arteriosclerosis, thrombosis, and vascular biology. 2018;38:829-842.
10.    Olsson M, Stanne TM, Pedersen A, Lorentzen E, Kara E, Martinez-Palacian A, Ronnow Sand NP, Jacobsen AF, Sandset PM, Sidelmann JJ, Engstrom G, Melander O, Kanse SM and Jern C. Genome-wide analysis of genetic determinants of circulating factor VII-activating protease (FSAP) activity. Journal of thrombosis and haemostasis :  2018;16:2024-2034.
11.    Grasso S, Neumann A, Lang IM, Etscheid M, von Kockritz-Blickwede M and Kanse SM. Interaction of factor VII activating protease (FSAP) with neutrophil extracellular traps (NETs). Thrombosis research. 2018;161:36-42.
12.    Etscheid M, Subramaniam S, Lochnit G, Zabczyk M, Undas A, Lang IM, Hanschmann KM and Kanse SM. Altered structure and function of fibrinogen after cleavage by Factor VII Activating Protease (FSAP). Biochim Biophys Acta Mol Basis Dis. 2018;1864:3397-3406.
13.    Cole JW, Xu H, Ryan K, Jaworek T, Dueker N, McArdle P, Gaynor B, Cheng YC, O'Connell J, Bevan S, Malik R, Ahmed NU, Amouyel P, Anjum S, Bis JC, Crosslin D, Danesh J, Engelter ST, Fornage M, Frossard P, Gieger C, Giese AK, Grond-Ginsbach C, Ho WK, Holliday E, Hopewell J, Hussain M, Iqbal W, Jabeen S, Jannes J, Kamal A, Kamatani Y, Kanse S, Kloss M, Lathrop M, Leys D, Lindgren A, Longstreth WT, Jr., Mahmood K, Meisinger C, Metso TM, Mosley T, Jr., Muller-Nurasyid M, Norrving B, Parati E, Peters A, Pezzini A, Quereshi I, Rasheed A, Rauf A, Salam T, Shen J, Slowik A, Stanne T, Strauch K, Tatlisumak T, Thijs VN, Tiedt S, Traylor M, Waldenberger M, Walters M, Zhao W, Boncoraglio G, Debette S, Jern C, Levi C, Markus H, Meschia J, Rolfs A, Rothwell P, Saleheen D, Seshadri S, Sharma P, Sudlow C, Worrall B, Stine OC, Kittner SJ and Mitchell BD. Genetics of the thrombomodulin-endothelial cell protein C receptor system and the risk of early-onset ischemic stroke. PloS one. 2018;13:e0206554.
14.    Sperling C, Maitz MF, Grasso S, Werner C and Kanse SM. A Positively Charged Surface Triggers Coagulation Activation Through Factor VII Activating Protease (FSAP). ACS applied materials & interfaces. 2017;9:40107-40116.
15.    Reiterer V, Figueras-Puig C, Le Guerroue F, Confalonieri S, Vecchi M, Jalapothu D, Kanse SM, Deshaies RJ, Di Fiore PP, Behrends C and Farhan H. The pseudophosphatase STYX targets the F-box of FBXW7 and inhibits SCFFBXW7 function. EMBO J. 2017;36:260-273.
16.    Kara E, Manna D, Loset GA, Schneider EL, Craik CS and Kanse S. Analysis of the substrate specificity of Factor VII activating protease (FSAP) and design of specific and sensitive peptide substrates. Thromb Haemost. 2017;117:1750-1760.
17.    Herold J, Nowak S, Kostin S, Daniel JM, Francke A, Subramaniam S, Braun-Dullaeus RC and Kanse SM. Factor VII activating protease (FSAP) influences vascular remodeling in the mouse hind limb ischemia model. Am J Transl Res. 2017;9:3084-3095.
18.    Byskov K, Boettger T, Ruehle PF, Nielsen NV, Etscheid M and Kanse SM. Factor VII activating protease (FSAP) regulates the expression of inflammatory genes in vascular smooth muscle and endothelial cells. Atherosclerosis. 2017;265:133-139.
19.    Leiting S, Seidl S, Martinez-Palacian A, Muhl L and Kanse SM. Transforming Growth Factor-beta (TGF-beta) Inhibits the Expression of Factor VII-activating Protease (FSAP) in Hepatocytes. The Journal of biological chemistry. 2016;291:21020-21028.
20.    Daniel JM, Reichel CA, Schmidt-Woell T, Dutzmann J, Zuchtriegel G, Krombach F, Herold J, Bauersachs J, Sedding DG and Kanse SM. Factor VII-activating protease deficiency promotes neointima formation by enhancing leukocyte accumulation. Journal of thrombosis and haemostasis : 2016;14:2058-2067.
21.    Cui XY, Tinholt M, Stavik B, Dahm AE, Kanse S, Jin Y, Seidl S, Sahlberg KK, Iversen N, Skretting G and Sandset PM. Effect of hypoxia on tissue factor pathway inhibitor expression in breast cancer. Journal of thrombosis and haemostasis : 2016;14:387-96.
22.    Chillo O, Kleinert EC, Lautz T, Lasch M, Pagel JI, Heun Y, Troidl K, Fischer S, Caballero-Martinez A, Mauer A, Kurz ARM, Assmann G, Rehberg M, Kanse SM, Nieswandt B, Walzog B, Reichel CA, Mannell H, Preissner KT and Deindl E. Perivascular Mast Cells Govern Shear Stress-Induced Arteriogenesis by Orchestrating Leukocyte Function. Cell Rep. 2016;16:2197-2207.
23.    Cheng YC, Stanne TM, Giese AK, Ho WK, Traylor M, Amouyel P, Holliday EG, Malik R, Xu H, Kittner SJ, Cole JW, O'Connell JR, Danesh J, Rasheed A, Zhao W, Engelter S, Grond-Ginsbach C, Kamatani Y, Lathrop M, Leys D, Thijs V, Metso TM, Tatlisumak T, Pezzini A, Parati EA, Norrving B, Bevan S, Rothwell PM, Sudlow C, Slowik A, Lindgren A, Walters MR, Consortium W-, Jannes J, Shen J, Crosslin D, Doheny K, Laurie CC, Kanse SM, Bis JC, Fornage M, Mosley TH, Hopewell JC, Strauch K, Muller-Nurasyid M, Gieger C, Waldenberger M, Peters A, Meisinger C, Ikram MA, Longstreth WT, Jr., Meschia JF, Seshadri S, Sharma P, Worrall B, Jern C, Levi C, Dichgans M, Boncoraglio GB, Markus HS, Debette S, Rolfs A, Saleheen D and Mitchell BD. Genome-Wide Association Analysis of Young-Onset Stroke Identifies a Locus on Chromosome 10q25 Near HABP2. Stroke. 2016;47:307-16.
24.    Bustamante A, Diaz-Fernandez B, Giralt D, Boned S, Pagola J, Molina CA, Garcia-Berrocoso T, Kanse SM and Montaner J. Factor seven activating protease (FSAP) predicts response to intravenous thrombolysis in acute ischemic stroke. International journal of stroke: 2016;11:646-55.
25.    Subramaniam S, Thielmann I, Morowski M, Pragst I, Sandset PM, Nieswandt B, Etscheid M and Kanse SM. Defective thrombus formation in mice lacking endogenous factor VII activating protease (FSAP). Thromb Haemost. 2015;113:870-80.
26.    Reichel CA, Hessenauer ME, Pflieger K, Rehberg M, Kanse SM, Zahler S, Krombach F, Berghaus A and Strieth S. Components of the plasminogen activation system promote engraftment of porous polyethylene biomaterial via common and distinct effects. PloS one. 2015;10:e0116883.
27.    Joshi AU, Orset C, Engelhardt B, Baumgart-Vogt E, Gerriets T, Vivien D and Kanse SM. Deficiency of Factor VII activating protease alters the outcome of ischemic stroke in mice. Eur J Neurosci. 2015;41:965-75.

Emneord: Hjerte- og karsykdom, Hjerneslag, trombose, aterosklerose, kogulasjon, fibrinolyse, proteaser, Blod og immunologi, Inflammasjon
Publisert 16. feb. 2012 09:33 - Sist endret 12. des. 2019 13:07

Kontakt

Postadresse
Postboks 1112 Blindern
0317 Oslo

Beøsksadresse
Avd. for molekylærmedisin
Domus Medica Gaustad
Sognsvannsveien 9
0372 Oslo

Gruppeleder